<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>25(1)</volume><submitter>Riess A</submitter><funding>Universitätsklinikum Tübingen</funding><funding>Deutsche Forschungsgemeinschaft</funding><pubmed_abstract>Mulvihill-Smith Syndrome (MSS) is a clinically complex and genetically unsolved nano-rare disorder with only 12 patients reported in the literature. Most patients (91%) have immunological impairments, succumb to infection, and might develop cancer later in life. Its pathogenesis remains elusive and therapeutic options are limited. We used single-cell MULTI-omics (sc-MULTI-omics), combining transcriptomics (gene expression, TCR, and BCR repertoire) and proteogenomic (Cellular Indexing of Transcriptomes and Epitopes by Sequencing; CITE-seq), to decipher the pathophysiology of nano-rare disease patient. We report a new patient who is a 16-year-old girl. She had an increased leukocyte counts and typical manifestations of MSS such as short stature, older appearance, multiple pigmented nevi, mic</pubmed_abstract><journal>Functional &amp; integrative genomics</journal><pagination>101</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12064584</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>sc-MULTI-omics approach in nano-rare diseases: understanding the pathophysiological mechanism of Mulvihill-Smith Syndrome.</pubmed_title><pmcid>PMC12064584</pmcid><pubmed_authors>Selting AS</pubmed_authors><pubmed_authors>Singh Y</pubmed_authors><pubmed_authors>Casadei N</pubmed_authors><pubmed_authors>Lysenkov V</pubmed_authors><pubmed_authors>Ossowski S</pubmed_authors><pubmed_authors>Roggia C</pubmed_authors><pubmed_authors>Riess O</pubmed_authors><pubmed_authors>Riess A</pubmed_authors></additional><is_claimable>false</is_claimable><name>sc-MULTI-omics approach in nano-rare diseases: understanding the pathophysiological mechanism of Mulvihill-Smith Syndrome.</name><description>Mulvihill-Smith Syndrome (MSS) is a clinically complex and genetically unsolved nano-rare disorder with only 12 patients reported in the literature. Most patients (91%) have immunological impairments, succumb to infection, and might develop cancer later in life. Its pathogenesis remains elusive and therapeutic options are limited. We used single-cell MULTI-omics (sc-MULTI-omics), combining transcriptomics (gene expression, TCR, and BCR repertoire) and proteogenomic (Cellular Indexing of Transcriptomes and Epitopes by Sequencing; CITE-seq), to decipher the pathophysiology of nano-rare disease patient. We report a new patient who is a 16-year-old girl. She had an increased leukocyte counts and typical manifestations of MSS such as short stature, older appearance, multiple pigmented nevi, mic</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 May</publication><modification>2026-04-08T19:45:49.893Z</modification><creation>2026-04-08T14:26:18.244Z</creation></dates><accession>S-EPMC12064584</accession><cross_references><pubmed>40343591</pubmed><doi>10.1007/s10142-025-01608-y</doi></cross_references></HashMap>